Introduction {#S1}
============

It is estimated that vaginal infections account for more than 10 million doctors' visits per year, and that 70% of episodes of vaginitis in premenopausal women are caused by bacterial vaginosis (BV) or vulvovaginal candidiasis (VVC; [@B7]). Especially if untreated, these infections may cause serious complications of the upper genital tract (e.g., endometritis, salpingitis, and pelvic inflammatory disease) leading to tubal scarring, infertility, or ectopic pregnancies ([@B47]; [@B36]). During pregnancy, they can increase the risk of preterm labor and low birth weight in the newborn ([@B30]). Further, some vaginal infections are associated with cellular abnormalities of the lower genital tract, which can lead to the development of cervical or vulvar dysplasia ([@B59]). To date, although standard therapeutic strategies have been shown to be effective, they are not resolute. The increased drug resistance in bacteria and fungi, commonly involved in vaginal infections is frequently associated with high recurrence rates and chronic infections. Furthermore, the extant antimicrobial therapeutic strategies cannot spontaneously restore the normal vaginal flora, which is characterized by a high population of *Lactobacillus* spp. ([@B50]). Based on these observations, novel antimicrobial approaches are required. This review focuses attention on the potential benefits of yeast probiotic-based strategies as novel prophylactic or therapeutic options for vaginal infections.

Vaginal Microbiota {#S2}
==================

The vaginal ecosystem contains many microorganisms, both anaerobic and aerobic, which are in a state of dynamic equilibrium ([@B26]). It is influenced by various factors such as age, sexual activity, pregnancy, contraception, phases of the menstrual cycle, and possible pathologies or therapeutic treatments. Recent studies have demonstrated that at least five vaginal community state types (CSTs) exist in women of healthy reproductive age ([@B59]; [@B26]), of which four are dominated by lactobacilli. In detail, CST-I is dominated by *Lactobacillus crispatus;* CST-II, by *Lactobacillus iners*; CST-III, by *Lactobacillus gasseri*; and CST-V, by *Lactobacillus jensenii.* CST-IV is defined as a "non-*Lactobacillus*-dominated" community, and consists of strict and facultative anaerobes belonging to the genera *Gardnerella*, *Atopobium*, *Mobiluncus*, *Corynebacterium*, *Peptococcus*, *Peptostreptococcus*, *Clostridium*, *Bifidobacterium*, *Propionibacterium*, *Eubacterium*, *Bacteroides*, and *Prevotella*.

Despite a wide body of knowledge about the composition of vaginal microbiota exists, little is known about the composition of the vaginal mycobiome. Recent studies ([@B31]; [@B8]) have reported that in healthy women, Ascomycota is the predominant phylum, followed by Basidiomycota and Oomycota. *Candida, Saccharomyces, Aspergillus, Cladosporium*, and *Alternaria* represent the commonly genera of the vaginal mycobiome ([@B31]; [@B20]). *Candida* is the most abundant and is present in approximately 20--30% of healthy women ([@B8]; [@B11]). A balanced local microbial community is essential for vaginal health. Any perturbation of the composition of the vaginal microbiota, particularly a reduction in the population of *Lactobacillus* spp., which is considered the main component of a healthy vaginal ecosystem, may predispose women to genital tract infections.

Vaginal Infections {#S3}
==================

The most common forms of vaginal infections are represented by VVC and BV. In particular, VVC affects women of reproductive age, and is caused by fungi belonging to the genus *Candida.* Among *Candida* species, *Candida albicans* (*C. albicans*) is responsible for almost 80--90% of all cases of VVC. A minority of cases (10--20%) is caused by other *Candida* species, including *Candida glabrata*, *Candida tropicalis*, and *Candida krusei* ([@B71]). *C. albicans* is a dimorphic fungus that can exist as both yeast and mold. In the yeast form, *Candida* can asymptomatically colonize the vaginal mucosa. However, under some circumstances, the yeast cells switch from the yeast to hyphae, which can breach mucosal surfaces, causing acute vulvovaginal infection. Furthermore, *C. albicans* is the main etiological agent responsible for a severe chronic infection known as recurrent VVC. Although over 50% of women develop VVC, approximately 8--10% of these women experience recurrences ([@B50]). VVC development is, usually, attributed to alterations in the delicate balance between *Candida* commensalism and the host environment in the vagina, caused by physiological or non-physiological changes. Several host-related and behavioral risk factors can predispose to VVC, including pregnancy, hyperglycemia, immunosuppression, antibiotic or glucocorticoid therapies, oral contraceptive use, intrauterine devices, and genetic predispositions. However, despite the increasing list of well-known risk factors, the role of the host response to the microorganisms in causing *Candida* vaginitis and recurrent episodes remains to be fully clarified ([@B28]).

Bacterial vaginosis is considered the most common form of vaginitis affecting fertile, premenopausal, and pregnant women ([@B7]). BV is often grouped together with trichomoniasis, a sexually transmitted infection caused by the parasite *Trichomonas vaginalis*, even though there are major differences in the etiology, pathophysiology, and transmission implications between the two. BV is not a true infection, but it is considered a complex imbalance in the physiological vaginal flora, where the normal population levels of *Lactobacillus* spp. are reduced and replaced by some of the less dominant and potentially pathogenic microorganisms, such as *Gardnerella vaginalis, Atopobium vaginae, Mobiluncus* spp., *Bacteroides* spp., *Mycoplasma hominis*, and *Prevotella* spp. ([@B75]; [@B80]). Microbiologically, BV is characterized by depletion of hydrogen peroxide (H~2~O~2~)-producing lactobacilli with an overgrowth of anaerobic bacteria. Although the exact mechanisms and sequence of events leading to the infective process have not yet been fully elucidated, *Gardnerella vaginalis* is thought to be a key player in the pathogenesis of BV, since it provides the niche suitable for colonization by anaerobic bacteria, which are primarily responsible for the clinical symptoms of BV ([@B80]; [@B35]). There is general consensus that BV is characterized by the presence of anaerobic polymicrobial biofilm, consisting mainly of *Gardnerella vaginalis* ([@B76]). Important features associated with the pathogenesis of this disease are: (i) the ability of *Gardnerella* to strongly adhere to vaginal epithelium forming a robust biofilm, (ii) the capacity to produce sialidase, an enzyme known to facilitate the destruction of the protective mucus on the vaginal epithelium, and (iii) the ability to trigger exfoliation of vaginal epithelial cells, which facilitates the spread of the pathogen to the underlying tissues.

Several studies have reported that multiple risks can predispose a woman to BV acquisition, including racial characteristics (black), smoking, low socioeconomic status, the presence of sexually transmitted diseases (STDs), and sexual behaviors ([@B44]; [@B51]). A growing body of evidence indicates that BV is consistently associated with an increased risk of STDs by parasites, like *Trichomonas vaginalis*, bacteria such as *Neisseria gonorrhoeae* and *Chlamydia trachomatis* ([@B4]), and viruses including human immunodeficiency virus (HIV; [@B17]; [@B16]) and herpes simplex virus type 2 (HSV-2; [@B15]). The increased risk of acquiring STDs may further contribute to damage to the female reproductive organs.

Conventional Antimicrobial Therapy {#S4}
==================================

Several strategies have been employed in the clinical setting for the treatment of VVC. Standard therapy involves topical application of vaginal ovules, creams, lotions, or oral drugs. Fluconazole, amphotericin B, nystatin, and flucytosine are the most common antifungal agents currently in use to treat VVC. Among these, topical azole and oral fluconazole are equally efficacious and remain the first-line therapy for managing uncomplicated cases of VVC. In chronic or recurrent cases of vulvovaginitis, the first choice of therapy is oral fluconazole ([@B19]). Although the standard treatment for VVC leads to relief of symptoms and negative cultures in 80--90% of patients ([@B68]), the main limitation of the current antifungal treatments is their inability to offer a long-term defensive barrier ([@B72]), facilitating relapses and a high recurrence rate. Possible mechanisms underlying recurrent VVC include genetic factors, reinfection from a sexual partner or from an endogenous source (the gut), persistence of fungi following treatment, probably due to emergence of resistant strains on the vaginal epithelium, and vaginal recolonization failure by *Lactobacillus* spp. ([@B49]; [@B42]; [@B72]).

The therapeutic strategies recommended for BV treatment include ([@B52]) oral or intravaginal metronidazole, or intravaginal 2% clindamycin cream ([@B14]), and alternatively, oral administration of clindamycin and tinidazole ([@B43]). In 2017, the FDA approved the use of secnidazole, a second-generation 5-nitroimidazole agent with a longer half-life than metronidazole and tinidazole for the treatment of BV ([@B73]; [@B77]). Until now, although the current therapies initially succeed in reducing the symptoms of BV, extended follow-up studies have reported recurrence rates in excess of 50% within 6--12 month from the onset of therapeutic treatment ([@B9]).

One possible reason for the failure of conventional treatments, and the high recurrence rates of BV, could be the strong polymicrobial biofilm that has been reported to be present in 90% of women with BV ([@B76]) and the high levels of drug-resistance found in *Gardnerella vaginalis* clinical isolates ([@B29]). [@B5] determined the *in vitro* susceptibility of 30 BV-associated biofilm-forming bacteria to metronidazole, tinidazole, and clindamycin and showed that all tested strains were resistant to metronidazole, and 67% of the tested strains were resistant to clindamycin. In addition, recent metagenome sequencing studies have identified at least four clades of *Gardenerella vaginalis* ([@B3]), of which two may be intrinsically resistant to metronidazole, providing another possible explanation for the BV persistence, even after appropriate therapies ([@B66]).

Therefore, it is evident that despite the use of standard antimicrobial agents, which remains the major strategy for treating vaginal infections, the high resistance and recurrence rates, the high probability of complications, and several adverse effects on beneficial vaginal microbiota underscore the need for novel antimicrobial therapeutic approaches.

Yeast-Based Probiotics as a Novel Therapeutic Approach {#S5}
======================================================

In recent years, probiotic-based strategies have shown to be a promising and valid tool for both prophylaxis and treatment of vaginal infections both as alternative or adjunctive treatment. According to the definition of the Food and Agriculture Organization/World Health Organization, probiotics are defined as "Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host" ([@B33]). Notably, a probiotic must to be safe for use in humans, and it must be effective, stable, and not be a carrier of acquired and/or transmissible antibiotic resistance. Therefore, a new assessment of safety, functionality, stability, and antibiotic resistance profile would be required before using any new microbial strain, even if it is one belonging to a species already in use. In addition, as the antimicrobial effect of a probiotic is generally strain-specific as well as disease-specific ([@B32]), a potential probiotic should be specifically chosen for a pathogen and disease and tailored to the individual patient. Probiotics can be used both orally or topically to prevent or treat vaginal infections, and currently neither route has a clear superior effect to the other. A pharmaceutical preparation of yeast-based probiotics for local treatment in different mucosal niches would be desirable.

Thus far, most microorganisms, used as probiotics, are cultivable components of the human microbiota and belong to the genera *Lactobacillus*, *Bifidobacterium*, and *Saccharomyces* ([@B6]), which are included in the category of "generally regarded as safe" (GRAS; [@B38]; [@B70]).

Over the last few years, interest around the use of yeast-based probiotics is increased, because not only they are naturally resistant to antibiotics, and, so, it's not necessary to evaluate their antibiotic resistance profile, but, also, because they can be used in patients undergoing antibiotic therapy. Due to these characteristics they provide a considerable advantage over bacterial-origin probiotics. Although many yeast species have been shown to possess the characteristics of a probiotic, such as *Kluyveromyces lodderae, Kluyveromyces marxianus* ([@B39]), *Kluyveromyces lactis*, *Yarrowia lipolytica* ([@B41]), and *Issatchenkia occidentalis* ([@B40]). *Saccharomyces boulardii* and *Saccharomyces cerevisiae* undoubtedly display the most probiotic properties. *S. boulardii* CNCM I-745 was the first strain that has been studied for use as probiotic in human medicine, and it is one of the recommended probiotics for the prevention and treatment of antibiotic-related diarrhea, including *Clostridium difficile-*associated diarrhea ([@B18]). Additionally, preclinical studies have shown that this *Saccharomyces* strain presents a beneficial effect against many gastrointestinal pathogens such as *Salmonella typhimurium*, *Shigella flexneri*, *Escherichia coli* (enteropathogenic and enterohaemorrhagic strains), *Vibrio cholerae*, *Rotavirus*, and *C. albicans* ([@B18]; [@B67]).

Many studies have, also, highlighted the beneficial effects of several *S. cerevisiae* strains on entheropatogenic bacteria ([@B45]; [@B53]; [@B46]; [@B21]; [@B78]; [@B69]; [@B64]), on inflammatory bowel diseases ([@B57]; [@B79]; [@B74]; [@B13]; [@B27]), and on pathogenic fungi (*C. albicans* and non-*albicans Candida* species, *Aspergillus flavus*; [@B58]; [@B1]; [@B40]; [@B63]). The potential mechanisms described include: inhibition of pathogen growth ([@B21]; [@B64]; [@B1]; [@B63]), inhibition of pathogen adherence to epithelial cells ([@B53]; [@B78]; [@B69]; [@B64]; [@B40]), immunomodulatory activity ([@B45]; [@B46]; [@B69]; [@B79]; [@B64]; [@B63]), inhibition of filamentation and biofilm development ([@B40]), and reduction of toxin production ([@B64]; [@B1]).

Recently we demonstrated, for the first time, that a *S. cerevisiae*-based approach may be a very promising and valid tool for both prophylaxis and/or treatment of vaginal diseases such as VVC ([@B12]; [@B55]; [@B23]) and BV ([@B65]).

These studies were performed with a well-characterized *S. cerevisiae* strain ([@B22]) owned by Lesaffre International, registered in the French National Collection of Cultures of Microorganisms (CNCM) under the number I-3856.

*Saccharomyces cerevisiae*-Based Probiotic Effects on Vaginal Candidiasis and Bacterial Vaginosis {#S6}
=================================================================================================

It is well known that the use of wide-spectrum antibiotics, including antifungal agents, leads to deep alterations in the vaginal microbiota, favoring the onset of vaginal infections. Using an *in vivo* imaging system, we demonstrated, in a mouse model of VVC, that the daily intravaginal administration of live *S. cerevisiae* (CNCM I-3856 strain) and, to a lesser degree, of inactivated *S. cerevisiae* (CNCM 1-3856 strain), elicited *C. albicans* clearance at levels similar to those obtained with fluconazole ([@B55]), the conventional drug used to treat *Candida* vaginitis ([@B82]; [@B83]). The beneficial effect of both live and inactivated *S. cerevisiae* was due to a co-aggregation of *Candida* and consequently to its inability to adhere to the mucosal surface, protecting the vaginal epithelium from the fungus induced damage ([@B55]). However, only the live and not the attenuated yeast strongly suppressed some of the crucial virulence factors of *C. albicans*, such as its capacity to switch from the yeast to the hyphal form and the ability to express aspartyl proteases ([@B55]; [@B23]). These effects were related to the ability of the live yeast to significantly inhibit the expression of two important hyphal growth-associated genes, in particular the hyphal wall protein 1 (HWP1) and extent of cell elongation 1 (ECE1), as well as the expression of two secretory aspartyl proteinases (SAPs), SAP2, and SAP6, which play a key role in the immunopathogenesis of vaginal candidiasis ([@B48]; [@B10]; [@B24]; [@B54]; [@B61]). The suppression of *SAP2* and *SAP6* gene expression mirrored the reduction of the inflammatory process associated with the pathogenesis of *Candida* vaginitis ([@B61]). Indeed, SAPs, through a direct chemotactic activity ([@B25]), promote the massive recruitment of neutrophils to the vaginal compartment, contributing to exacerbate the pathological inflammation associated to *Candida* infection ([@B56]; [@B81]). Additionally, in our experimental models, *S. cerevisiae* has been shown to influence the host immune response by increasing the antimicrobial property of polymorphonuclear (PMN) cells, in terms of reactive oxygen species (ROS) hyperproduction and killing activity ([@B23]), which generally appears to be reduced or absent in patients with vaginal candidiasis ([@B84]). Since ROS play an important role in triggering the extracellular trap ([@B37]), which is one of the main mechanisms by which neutrophils can kill non-phagocytosed microorganisms, our results suggest that *Saccharomyces* may be able to stimulate this process *via* increasing the ROS production.

Moreover, the intravaginal administration of the live CNCM I-3856 strain downregulated the production of interleukin (IL)-8, a neutrophil chemotactic factor, which plays a role in the pathogenesis of human VVC ([@B61]). As we have recently found that in patients with VVC high IL-8 levels in vaginal fluid are positively associated with *Candida* infection ([@B62]), IL-8 downregulation may represent an intriguing strategy for treatment of *Candida* vaginitis. These findings are supported by recent clinical results showing that daily oral administration of 500 mg (5 × 10^9^ CFU/mL) of live CNCM I-3856, for 56 days, in women receiving conventional antifungal drugs for VVC, was effective in controlling the vaginal *C. albicans* load and, also, in preventing VVC recurrence ([@B12]). These data confirmed the therapeutic activity of *S. cerevisiae* CNCM I-3856 and further highlight the effectiveness of the oral administration of this strain in treating VVC. Of note, no serious side effects were observed in CNCM I-3856 yeast treated patients, confirming the safety and well-tolerability of this probiotic ([@B57]; [@B74]; [@B12], [@B13]). However, future studies should be carried out for a better understanding of dynamics within *Saccharomyces* given orally can colonize the vaginal microenvironment.

Despite accumulation of data regarding the protective effect against mucosal candidiasis, no studies have investigated the impact of yeast-based probiotics in BV. Recently, our research group demonstrated, for the first time, that vaginal administration of *Saccharomyces* CNCM I-3856 strain, also, had beneficial effects in a mouse model of *G. vaginalis* infection ([@B65]). Indeed, this strain significantly reduced the vaginal bacterial load and removed up to 90% of *Gardnerella* bacteria infecting uterine horns, suggesting that the CNCM I-3856 strain presents a potential therapeutic efficacy in treating not only vaginal candidiasis but, also, bacterial uterine infections. This is a noteworthy effect because several studies have identified *G. vaginalis* as an etiological agent in puerperal sepsis and in septic and endometritis abortion ([@B2]; [@B60]; [@B34]). The efficacy of this strain was associated with a marked reduction of *Gardnerella* virulence factors, including sialidase activity and inhibition of vaginal epithelial cells exfoliation. Additionally, mechanistic effects include the direct interference of CNCM I-3856 yeast with *Gardnerella* adherence to vaginal tissues, and its ability to exert a displacement of adhering bacteria to vaginal or cervical epithelial cells. [Table 1](#T1){ref-type="table"} summarizes the beneficial effects of *S. cerevisiae* CNCM I-3856 in the prevention and treatment of vaginal infections.

###### 

Effect of *S. cerevisiae* CNCM I-3856 on vaginal infections.

  *S. cerevisiae* CNCM I-3856 effects on VVC                                 References
  -------------------------------------------------------------------------- ----------------
  Reduction of *C. albicans* vaginal load                                    [@B12]; [@B55]
  Inhibition of *C. albicans* adhesion on vaginal epithelial cells           [@B55]
  Induction of *C. albicans* co-aggregation                                  [@B55]
  Suppression of *C. albicans* ability to switch from yeast to hyphal form   [@B55]
  Suppression of *C. albicans SAP2* and *SAP6* expression                    [@B55]; [@B23]
  Reduction of vaginal epithelial cell damage                                [@B55]
  Reduction of IL-8 production. Reduction of PMNs vaginal recruitment        [@B23] [@B23]
  Enhancement of PMNs antimicrobial activity                                 [@B23]
                                                                             
  ***S. cerevisiae* CNCM I-3856 effects on BV**                              **References**
                                                                             
  Reduction of *G. vaginalis* vaginal and uterine horns load                 [@B65]
  Inhibition of *G. vaginalis* adhesion on vaginal epithelial cells          [@B65]
  Displacement of *G. vaginalis* adhered to vaginal epithelial cells         [@B65]
  Reduction of *G. vaginalis* sialidase activity                             [@B65]
  Reduction of vaginal epithelial cells exfoliation                          [@B65]

Conclusion and Future Perspectives {#S7}
==================================

Vulvovaginal candidiasis and BV are the most prevalent vaginal infections in women, and both are characterized by an extremely high recurrence rate mostly due to the emergence of resistant strains against the commonly used antimicrobial drugs. Probiotic administration could represent an alternative or adjuvant therapeutic approach for preventing and/or treating VVC and BV. Despite several preclinical researches and a multitude of clinical trials, to date, few studies have analyzed the effects of yeast-based probiotics on vaginal infections. This is the first overview of the beneficial effects of a probiotic yeast in preventing and/or treating some vaginal mucosal infections. Local and/or oral treatment with *S. cerevisiae* attenuated the course of VVC, as well as, BV in a mouse experimental system. The positive effect of this treatment was confirmed with a controlled clinical trial in women with vaginal candidiasis. The mechanism appears to be associated with a direct effect of *S. cerevisiae* on pathogens, as well as, in the case of VVC, its immunobiotic properties. These features open the door to future clinical studies to determine if *S. cerevisiae* CNCM I-3856 can reduce the colonization of *C. albicans* and/or *G. vaginalis* on human mucosal surfaces, attenuate VVC and/or BV symptoms, and enhance the antimicrobial effect of standard therapeutic approaches.
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